Tryptophan Hydroxylase 1 antibody (full length)

Catalog No. ABIN7879211

This Mouse Monoclonal antibody specifically detects Tryptophan Hydroxylase 1 in IHC (p). It exhibits reactivity toward Human.

Quick Overview for Tryptophan Hydroxylase 1 antibody (full length) (ABIN7879211)

Target: Tryptophan Hydroxylase 1 (TPH1)

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This Tryptophan Hydroxylase 1 antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Grade: Carrier-free

Clone: TPH1-7662

Product Details anti-Tryptophan Hydroxylase 1 Antibody

Binding Specificity: full length

Purpose: Tryptophan Hydroxylase 1 Antibody (azide and preservative free)

Purification: Protein A/G affinity

Immunogen: Recombinant full-length human TPH1 protein was used as the immunogen for the Tryptophan Hydroxylase 1 antibody.

Isotype: IgG2, kappa

Application Details

Application Notes: Optimal dilution of the Tryptophan Hydroxylase 1 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: -20 °C

Storage Comment: Aliquot the Tryptophan Hydroxylase 1 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for Tryptophan Hydroxylase 1

Target: Tryptophan Hydroxylase 1 (TPH1)

Alternative Name: Tryptophan Hydroxylase 1

Background: Phenylalanine hydroxylase (PAH), tyrosine hydroxylase (TH) and tryptophan hydroxylase (TPH) comprise a small family of monooxygenases that use tetrahydropterine as a cofactor during the catabolism of aromatic L-amino acids. PAH, TH and TPH all contain catalytic domains with an amino-terminal regulatory domain and a short carboxy-terminal tetramerization domain. Each of these enzymes also contains a single ferrous iron atom, which is bound to two histidines and a glutamate, and is likely to be involved in the formation of the hydroxylating intermediate. TPH is both the first and rate-limiting-step in the biosynthesis of serotonin in the central nervous system and melatonin in the pineal gland. Alteration of TPH function may be a key factor in the pathology of several neuropsychiatric disorders associated with serotonin, including depression, aggression, alcoholism and schizophrenia. For instance, LDOPA, which is used as a common therapy for Parkinson s disease (PD) patients, inhibits TPH function which, subsequently, is thought to contribute to the onset of depression in PD patients.

UniProt: P17752

Pathways: Feeding Behaviour